Scientific Research

Added after Anoxia-Reoxigenation Stress, Genistein Rescues from Death the Rat Embryo Cortical Neurons

Carmen Arce [1], José Luis Arteaga [1], Eduardo Sánchez-Mendoza [1], María Jesús Oset-Gasque [1], Sixta Cañadas [1], María Pilar González [1,2]

[1]Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Universidad Complutense, Madrid, Spain; [2]Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu, Madrid, Spain
Email: pilarg@farm.ucm.es

ABSTRACT

Estrogens and phytoestrogens have neuroprotective effect against neuronal damage induced by cerebral ischemia /reperfusion (I/R) injury. In preceding studies, the phytoestrogen effects have been assessed by administration previous to the ischemic period, conditions which are unusual to apply to the treatment of human stroke. Here we present a study on neuroprotection afforded by genistein on rat embryo cortical neurons subjected to oxygen and glucose deprivation (OGD) followed by re-oxigenation, when added after the stress stimulus. At 1 and 2 h of OGD times and after 24 h of reperfusion, cell viability, necrotic, apoptotic and autophagic cell death and different parameters related to oxidative stress and mitochondrial dysfunction were measured in the absence and presence of 1 µM genisteine. We found an increasing loss of neuronal viability after 1-5 h of OGD which was only reversed in part by 24 h of reperfusion. These changes were preceded by increases in ROS generation, caspase-3 activation, LDH release and increase in LC3B lipidation, indicative of autophagia. Treatment with 1 µM genistein during the 24 h reperfusion significantly attenuated neuronal necrosis and autophagia induced by 1 and 2 h of OGD exposure. Genistein also decreased ROS generation and lipid-peroxidation induced by 2 h of OGD. These results suggest an important neuroprotective effect of genistein against transient post-ischemic-like conditions.

Keywords: *Cortical Neurons, Oxygen-glucose Deprivation, Brain Ischemia, Neuronal Death, Necrosis, Apoptosis, Autophagy, Neuroprotection, Neurorepair, Phytoestrogens, Genistein*

1. Introduction

Global cerebral ischemia is a clinical outcome that occurs as consequence of different conditions like cardiac arrest, coronary artery bypass surgery and reversible severe hypertension. All these events are the cause of a dramatically reduced blood supply of oxygen and nutrients, as glucose, which are the responsible for cellular damage. Studies performed during the last 20 years have identified several biochemical and cellular events that lead to ischemic neuronal degeneration [1,2]. Although the management of stroke has improved remarkably over the last decade due mainly to the use of thrombolysis, moreover, nowadays there is a growing interest to develop treatments aimed to promote repair and regeneration of brain tissue damaged by ischemia, which could be more effective than neuroprotection on the brain recovery after ischemia.

Our increasing knowledge concerning with the ischemic cascade is leading to a considerable development of pharmacological tools, suggesting that each step of this cascade might be a target for cytoprotection. Thus, many neuroprotective drugs, such as calcium channel blockers, antioxidants or free radical scavengers, GABA agonists, glutamate antagonists, growth factors, NO inhibitors, phosphatidylcholine precursors and so on, have been studied in experimental stroke models (for review, see [3]). However, very few have shown efficacy in clinical trials. Among them, caspase inhibitors to reduce apoptosis and estrogen or its derivatives, phytoestrogens, have been proposed as future neuroprotective treatment [4,5].

In vivo and in vitro studies have demonstrated powerful neuroprotective effects of estrogens against a variety of insults. In rodents, estrogen reduces injury caused by focal cerebral ischemia [6] and global ischemia [7]. In vitro,

similar neuroprotective effects have been demonstrated in primary cortical [8-10], hippocampal [11-13] and mesencephalic cultures [14]. Furthermore, these neuroprotective effects appear to utilize multiple mechanisms depending on the injury and cell type [5,15].

It is increasingly clear that physiological doses of isoflavones, which can behave as phytoestrogens, can mimic some of the neuroprotective effects of estrogens. [16-18]. In vitro some soy isoflavones can protect primary neurons from glutamate toxicity [19], thapsigargin-induced apoptosis [20], and β-amyloid toxicity [21]. Several studies have indicated that genistein administration prevents delayed neuronal death after transient global cerebral ischemia [22], inhibits the lipid peroxidation induced by pro-oxidant agents in cultured cortical neurons [23] and attenuates the oxidative stress and neuronal damage following cerebral ischemia in rat hippocampus [24]. However, the mechanisms underlying protection from ischemic injury remain unclear. Recently, Schreihofera and Redmond, [17] have shown that pre-treatment with dietary levels of soy phytoestrogens can mimic neuroprotective effects observed with estrogen. Nevertheless, in all these works estrogen and phytoestrogens have been studied as neuroprotective agents but it has not been studied their possible effects on neurorepair in post-ischemic period, in spite that it is in this time when protection is necessary after an ischemical event. The present study was performed to test the ability of the phytoestrogen genistein to inhibit neuronal death in the post-ischemic period and to obtain further evidence about the molecular mechanisms by which phytoestrogens exercise these potential neuroprotective and neurorepairing effects. The study has been performed by using cortical neurons in primary cultures subjected to oxygen-glucose deprivation (OGD), since this has been proved to be a good model to test the mechanisms of neuroprotective agents in brain ischemia. Our results suggest that genistein may protect neurons from OGD in the post-ischemic period by attenuating oxidative stress, lipid peroxidation, and necrotic and autophagic cell death.

2. Material and Methods

2.1. Materials

Tetramethylrhodamine methyl ester (TMRM) and 2,7 dichlorodihydro-fluorescein diacetate (2,7 DCF-DA) and bis-[1,3-diethyl-thio-barbiturate]-trimethine-oxonol (bisoxonol) were purchased by Molecular Probes (Eugene, OR). Minimum Essential Eagle's Medium (EMEM) was from Bio-Whittaker, and Foetal Calf (FCS) was from Sera-Lab (Sussex, England). Other chemicals were reactive grade products from Merck (Darmstadt,

Germany). Anti-rabit microtubule associated protein light chain 3 (LC3B) antibody was from Cell Signallyng Technology Inc. (Danvers, MA).

2.2. Cell Isolation and Culture

Foetal rat brains of 19 days gestation were used. Brain neurons were obtained as described in [25]. Isolated neurons were suspended in EMEM medium containing 0.3 g/l glutamine, 3 g/l glucose, 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells, at density of 10^6 cells/cm/well, were placed on plastic Petri dishes, treated with 10 µg/ml poly-D-lysine, so that the cells could attach themselves to these plates. Incubations were made in a humidified incubator with 5% CO2/95% air at 37°C. After 72 hours, the incubation medium was replaced by fresh medium to which 10 µM of cytosine arabinoside was added to prevent overgrowth of contaminating glial cells. Cells were used after 7 days of culture. Cell purity was checked by both, cells staining with cresyl violet to identify neurons, and immunocytochemistry with the specific anti-GFAP antibody [25] to identify glial cells. Under these conditions, the glial cell number in the cultures was of $8.3 \pm 3.6\%$ of the total cell population (neurons + glial cells).

2.3. Oxygen-glucose Deprivation (OGD)

After 7 days of culture, the medium was removed and replaced by a glucose-free balanced salt Locke medium (composition (mM) NaCl 140, KCl 4.7, KH2PO4 1.2, CaCl2 2.5, MgSO4 1.2 and HEPES 15, pH 7.5). Multiwells were then placed in a gassed chamber equipped with gas entry and outflow devices, the chamber was then sealed and placed in the gassed incubator in an atmosphere of 95% N_2/5% CO_2 at 37°C for 1 or 2 h. OGD was terminated by removing the cultures from the chamber. These cells were considered as cells treated with OGD. In some multiwells, after this treatment, the OGD cultured medium was replaced by normal medium (EMEM containing 3 g/l glucose) and the multiwells were returned to the incubator under normoxic conditions (95% air/5% CO_2). This treatment was considered as reperfusion. The time of reperfusion of OGD-neurons was of 24 h. Control experiments were performed always in parallel, so, after 7 days of culture, the medium was removed and replaced by fresh normal medium EMEM containing 3 g/l of glucose. Control cells were kept at incubator under this condition during 1 or 2 h. Then, OGD-neurons were processed as indicated in each case.

2.4. Assessment of Cell Viability

Cell viability was determined by the XTT test, based on the ability of living metabolically active cells to reduce

the yellow tetrazolium salt (XTT) to form an orange formazan dye, which quantity directly correlates to the number of living cells. Measurements were preformed as described [25]. Briefly, control and treated neurones (2 × 10^5) were incubated with the XTT solution at 0.3 mg/ml final concentration and the orange formazan dye formed was spectrophotometrically quantified using an ELISA plate reader, at 450 nm (reference 650 nm). Results were expressed as percentages with respect to the control cells.

2.5. Measurement of the ROS Formation

To assay the ROS formation, 2,7-dichlorodihydrofluorescein diacetate (H_2DCF-DA), a non-fluorescent lipophilic reagent, was used. HDCF-DA enters into the cells, where it is transformed into 2,7-dichloro dihydrofluorescein (H_2DCF) by the action of intracellular estearases. H_2DCF is oxidized to fluorescent DCF by hydrogen peroxide. H_2DCF-DA (5 μM) was added to the cells, before subjectting them to the different treatments and then the incubation medium was removed, the cells were washed twice with PBS and the fluorescence was measured in a FL600-Bio Tek spectrofluorimeter with filters of 485/20 nm exc and 530/25 nm em. Results were expressed as arbitrary fluorencence units (AFU) ratios.

2.6. Lactate Dehydrogenase (LDH)

LDH activity was measured as the rate of decrease of the absorbance at 340 nm, resulting from the oxidation of NADH to NAD^+ as described [25]. Briefly, the culture medium was collected and the neurones were lysed with 0.1 M Tris-HCl (pH 7.4) containing 0.1% Triton X-100, cell suspension was centrifuged at 13,000 g during 5 minutes and LDH activity measured in both preparations, culture medium and cells supernatant. Activity of the LDH release is given as percentage of release of LDH with respect to the total LDH content (LDH in the culture medium plus LDH inside the cells).

2.7. Caspase-3 Activity Measurement

Control and treated cortical neurones were washed rapidly with PBS and lysed by cell lysis buffer (10 mM Tris-HCl, 10 mM NaH_2PO_4/Na_2HPO_4, pH 7.5, 130 mM NaCl, 0.5% Triton X-100, 10 mM $Na_4P_2O_7$). Lysates were centrifuged at 13,000 g for 5 minutes and caspase-3 activity was measured in the supernatants. Supernatants with at least 20 μg of protein were incubated in caspase-3 assay buffer (20 mM HEPES, pH 7.5, 10% glycerol, 2 mM DTT), containing 20 μM Ac. DEVD-AMC. [N-acetyl-Asp-Glu-Val-Asp-(7-amino-4-methylcoumarin)] at 37˚C during 2-4 h. The fluorogenic AMC liberated from Ac-DEVD-AMC was monitored using a spectro fluorimeter (Bio-Tek FL 600) with an excitation wavelength of 360/20 nm and an emission wavelength range 460/20 nm.

Under these conditions, the caspase-3 activity was linear during 6 h. Enzymatic activity is expressed as arbitrary fluorescence units, after 3 hours, per μg protein (AFU/3 h/μg protein).

The cell protein contents were monitored by the Bradford technique [26].

2.8. Mitochondrial Membrane Potential Assay

Mitochondrial membrane potential was measured according to Lalitha Tenneti *et al.* [27], with few modifications. Control and treated cells were washed with PBS and incubated for 30 min with 500 nM of TMRM dissolved in Locke medium (140 mM NaCl, 4.4 mM KCl, 2.5 mM $CaCl_2$, 1.2 mM $MgSO_4$, 1.2 mM KH2PO4, 4 mM NaHCO3, 5.5 mM glucose and 10 mM HEPES, adjusted to pH 7.5). Then, the cells were washed with PBS, and the fluorescence was measured with a FL600-BioTek spectrofluorimeter using filters of 530/25 nm exc. and 590/35 nm em.

2.9. Plasma Membrane Potential Measurement

Changes in the membrane potential (PMP) of neurons were monitored with the fluorescent dye bisoxonol (bis-[1,3-diethyl-thio-barbiturate]-trimethineoxonol), which is a lipophylic anion whose distribution across the membrane is dependent upon the membrane potential. Thus, an increase in bisoxonol fluorescence indicates that the membrane has been depolarised, allowing more of this negatively charged dye to enter the cells [28]. The control neurons, and neurons after treatment were washed and incubated with 0.2 μM bisoxonol for 30 min. After that, bisoxonol was removed, the cells were washed with PBS and suspended in PBS and fluorescence was measured at wavelengths of 540 nm excitation and 565 nm emission, and monitored with a FL600-BioTek spectrofluorimeter. Fluorescence intensity was reported in arbitrary fluorescence units (AFU).

2.10. ATP Determination

ATP analysis was performed by using the luciferase reaction. Cells were lysed with 0.4 M perchloric acid and the lysates neutralized with 1 M KOH under ice. The cellular extract was centrifuged and supernatant were kept at 0˚C. Aliquot samples were assayed immediately with firefly luciferase/D-luciferin as indicated in the test protocol (ATP Bio-Orbit Kit) and 2 mM of EDTA in 0.1 M Tris-acetate buffer, pH 7.5. The increase in chemiluminiscence was recorded in a Bio Orbit 125 luminometer. For calibrating the light signals, 10 pmol of ATP dissolved in Tris-acetic buffer was injected into each sample, and luminescence signal was determined. ATP cellular content was expressed as arbitrary fluorescence units (AFU). Intracellular ATP content in basal conditions was

of 670 ± 32 pmol ATP/10^6 cells.

2.11. Measurement of Lipid Peroxidation

The membrane lipid peroxidation in neurons was assayed according to Fraga *et al*. [29]. After OGD treatment of neurons, the culture medium was removed and cells were washed twice with PBS, and 0.1 ml of ethanol solution of butylated hydroxytoluene (4%), 0.5 ml of SDS (3%) and 0.3 ml of phosphotungstic acid (10%) was added to the neurons. The suspension was shaken and incubated at 100˚C for 45 min, and then 1 ml of 2-thiobarbituric acid (0.7 %) and 2 ml of HCl (0.1 N) were added. Once the suspension was cooled, 3 ml of n-butanol was added, shaken, and centrifuged at 2,000 g for 10 min. Then, the cells were washed with PBS, and the fluorescence was measured in the butanol phase with a FL600-BioTek spectrofluorimeter using filters of 515 nm exc. and 555 nm em.

2.12. Western Blot

Cortical neurons were plated on 12 well plates and treated as indicated in oxygen-glucose-deprivation section. Cells were washed, harvested, and lysed and western blot was performed as described by Figueroa *et al*. [25]. Rabbit LC3B (1/2000) was used as primary antibody, and rabbit peroxidase-conjugated IgG (1/2000) was used as secondary antibody. The antibody-reactive bands were revealed by enhanced chemiluminiscence (ECL western detection kit from Santa Cruz Biotechnology, Inc).

2.13. Data Analysis

Data are presented as means $\pm$ SEM of three or four separated experiments from different batches of cells from different cell cultures, each one performed in triplicated. Statistical comparisons were made using the Student's t test. This is a parametric test which studies differences between two populations. Results are means $\pm$ SEM of three separate experiments, from cells of different cultures, each one performed in triplicate. Values of $p < 0.05$ were considered as statistical significant. (*) = $p < 0.05$, (**) = $p < 0.01$ and (***) = $p < 0.001$.

3. Results

3.1. Genistein Reduces the Loss of Neuronal Viability Induced by OGD

As observed in **Figure 1(a)**, exposure of cortical neurons to OGD induced a loss in cell viability which was proportional to the OGD time. Exposure of cortical neurons to 1h OGD induced a loss in cell viability of about 40%, effect which was significantly reversed by 24 h of reperfusion (**Figure 1(b)**) but without reaching the control value.

(a)

(b)

Figure 1. Effect of oxygen glucose deprivation (OGD) on cell viability. (a) Effect of OGD exposure times on cell viability; (b) Effect of 24 h of reperfusion after 1 h OGD, in the absence or presence of genistein, on cortical neuron viability.

The addition of 1 μM genistein during the 24 h post-ischemic period, at the beginning of reperfusion, increased the neuroprotective effect induced by reperfusion alone and almost completely reverted the loss in cell viability induced by OGD (**Figure 1(b)**).

3.2. Genistein Attenuates the Necrotic Cell Death Induced by OGD

As a loss in cell viability is indicative of cellular death, necrosis, apoptosis and autophagy were studied. Results from **Figure 2(a)** show that OGD induced an increase in LDH release which is dependent on the cells exposure time to OGD. The LDH increase, after 2 h of OGD treatment, coincides with the loss in cell viability at this time (about 50% in both cases). After 2 h of OGD, a period of 24 h of reperfusion did not stop the LDH release although it was lower than during OGD treatment (**Figure 2(b)**). This means that during the OGD treatment the neurons have suffered a cellular membrane damage which is impossibly to repair during reperfusion. However, the presence of genistein during reperfusion reversed the necrotic death to a great extend (**Figure 2(b)**).

(a)

(b)

Figure 2. Effect of OGD on LDH release. (a) Effect of OGD time on LDH release; (b) Effect of 24 h of reperfusion after 2 h OGD, in the absence and presence of 1 μM genistein on LDH secretion.

Figure 3. Effects of OGD and reperfusion, in absence and presence of 1 μM genistein, on intracellular levels of ATP.

(a)

(b)

Figure 4. Effect of OGD on ROS formation. (a) Effect of OGD exposure times on ROS formation; (b) Effect of 24 h reperfusion, in absence or presence of genistein, after 2 h of OGD.

3.3. Genistein Protects Againts ATP Lost

Since it is known that necrosis is associated with a loss in intracellular ATP, the intracellular levels of this parameter were studied. Results from **Figure 3** show that after 2 h of OGD there was a great reduction in the intracellular ATP levels which is in accordance with the cellular death produced by necrosis (see **Figure 2(a)**). During reperfusion the ATP levels continuously decay although at lower levels than in the case of the OGD condition alone (**Figure 3**). However, when reperfusion was performed in the presence of 1 μM genistein, a light but significant increase in the ATP content was observed with respect to that in the absence of genistein (**Figure 3**).

3.4. Genistein Protects Cortical Neurons against ROS Generation Induced by OGD

As the ROS formation could be an inductor of death by necrosis, this parameter was also measured. Results from **Figure 4(a)** indicate that the ROS generation is dependent on time of cells exposure to OGD. During the 24 h of reperfusion, after 2 h of OGD, ROS levels were significantly reduced in about a 30% with respect to the ROS induced for OGD. The treatment with 1 μM genistein, during the 24 h reperfusion period after OGD, induced a total reversion of the ROS levels induced by the OGD treatment (**Figure 4(b)**).

3.5. Genistein Protects Neurons against Lipid Peroxidation Induced by OGD

It is known that ROS may produce lipid peroxidation, being this process the responsible for the necrotic cell death. We measured this parameter under the OGD conditions and the results showed an increase in lipid peroxidation after 2 h of OGD (**Figure 5**). During the 24 h of reperfusion, after 2 h of OGD, lipid peroxidation levels were significantly reduced in about a 65% with respect to that induced by OGD, although they were higher

      NM

than in the control. The treatment with 1 μM genistein, during the 24 h reperfusion period after 2 h of OGD treatment, produced a total reversion of the increase in lipid peroxidation induced by the OGD treatment (**Figure 5**).

3.6. Genistein Doest not Protect Neurons against Apoptotic Cell Death Induced by OGD

Knowing that in this OGD model neurons die by necrosis, the possibility of an apoptotic cell death was also checked and caspase-3 activity was measured as indicator of this process. In our OGD model the cells were cultured in absence of serum, then, as the serum deprivation induces apoptosis in cortical neurons [25] a positive control of apoptosis like the absence of serum (trophic factors) was used. Results from **Figure 6(a)**, indicate that the only serum deprivation was able to induce an increase in caspase-3 activation, being this effect directly proportional to the time the cells were cultured without serum. On the other hand, when these cells were subjected to OGD for different times, the caspase-3 activity was also significantly increased with respect to the treatment times. These effects were higher than those found for neurons cultured in absence of serum. Thus, the OGD treatment "perse" was also able to induce additional increases in caspase-3 activation (**Figure 6(a)**), although, at the low OGD treatment (1 to 5 h), the increase in caspase-3 activity with respect to the cells cultured in absence of serum was lower than those produced at the longer OGD conditions (24 h). The increase in caspase-3 activity induced by 2 h OGD was significantly reduced during 24 h of reperfusion and, in this case, 1 μM genisteine had not any additional effect (**Figure 6(b)**).

3.7. Genistein Protects Mitochondrial Membrane Potential without Affecting Plasma Membrane Potential

One of the mechanisms of apoptosis cell death induction is mitochondria malfunction. In order to check the in

(a)

(b)

Figure 6. Caspase-3 activation in cortical neurons exposed to OGD. (a) (-OGD) = action of time serum deprivation on cortical neurons in culture. (+OGD) = Effect of different OGD exposure times on caspase-3 activity. The activity of caspase-3 at 0 time (control) was 5.9 ± 0.4. (b) Effects of 24 h of reperfusion after 2 h of OGD exposure in absence and presence of 1 μM genistein.

volvement of mitochondria in apoptotic neuronal death induced by OGD, the possible variations in mitochondrial membrane potential (MMP) induced by the OGD treatment were checked. Results from **Figure 7(a)** show that 1 h of OGD produces a significant increase in MMP. On the other hand, 24 h of reperfusion in absence of genistein, after 1 h of OGD, decreased the TMR signal with respect to the control. However, when the reperfusion is performed in presence of 1 μM genistein the MMP reach the values of the control cells. By contrast with plasma membrane potential (PMP), 1 h of OGD treatment did not affect the potential of the cellular membrane, in this case genistein had not any effect on this parameter (**Figure 7(b)**).

3.8. Genistein Attenuates the Autophagic Cell Death Induced by OGD and Reperfusion

It is known that neurons can undergo more than one type of programmed cell death (PCD), not only apoptosis (or type I PCD) but also autophagy (or type II PCD). Autophagy was initially described as a process in which cytoplasmic material is degraded in lysosomes, providing nutrients for survival. However, autophagic features have also been observed in cells exposed to pathological insults as well as in remodelling tissues [30,31]. Because

Figure 5. Effects of OGD and reperfusion on lipid peroxidation, in the absence and presence of 1 μM genistein.

Figure 7. Effect of OGD and reperfusion in absence and presence of 1 μM genistein on mitochondrial (MMP) and cellular membrane (PMP) potential [A]: Action on MMP [B] Effect on PMP.

Figure 8. Time-course effects of OGD and reperfusion, in absence and presence of 1 μM genistein, on LC3B lipidation. Western blot analysis of LC3BI and LC3BII was performed in extracts of cortical neurons subjected to OGD exposure and 24 h reperfusion, in the absence or presence of 1 μM genistein, at indicate times, using a LC3B antibody. (a) Representative LC3B western blot is shown. (b) Data are expressed as ratios over basal control and are mean ± SEM of two experiments each one performed in duplicate.

several recent studies have shown that autophagy is involved in ischemic brain damage [32,33] and nutrient deprivation has been shown to lead cell to autophagia, we check in this paper the possibility that in the OGD experimental ischemia model used here, cortical neurons could drive to enter in an autophagic mechanism.

To characterize autophagy, we carried out the assay of LC3B lipidation (increase in LC3B-II from LC3BI) measured by western blot. As it could be appreciated in **Figure 8**, OGD was able to induce a significant increase in LC3B-I lipidation to the autophagosomal LC3B-II in cortical neurons. Autophagic cell death induced by OGD was kept among 1 to 5 h of treatment, although the maximum autophagia levels were observed at 1 h of OGD treatment. At higher OGD exposure 2 and 5 h, the autophagia was lower than at 1 h exposure but the values were higher than in control cells. 24 h of reperfusion reversed in part this parameter. However, the reperfusion in presence of 1 μM of genistein completely reversed LC3B lipidation.

4. Discussion and Conclusions

Epidemiologic data show that populations which consume diets rich in phytoestrogens have low incidence in coronary artery diseases [34,35]. Several studies have indicated that genistein administration prevents delayed

neuronal death after transient global cerebral ischemia [22,36,37] and attenuates oxidative stress and neuronal damage following cerebral ischemia in rat hippocampus [24] and inhibits the lipid peroxidation induced by pro-oxidant agents in cultured cortical neurons [23]. However, in all these works phytoestrogens have been studied as neuroprotective agents when they are administered in the period previous to ischemia and not in the postischemic period. Nevertheless it is in this time when protection is necessary after an ischemic event. Therefore, the present study was performed to test the ability of the phytoestrogen genistein to inhibit neuronal death in the post-ischemic period.

In the OGD model described here we found that there was a loss in cell viability which was accompanied by necrotic and apoptotic cell death, and we demonstrated that both death processes are time-dependent. The existence of a necrotic cortical neuron death, induced by the OGD model, is supported by the decrease in the intracellular ATP levels, the great ROS generation and the production of lipid peroxidation. This is in accordance with Traystman *et al.* [38] and Matsuo *et al.* [39] who found that a great ROS generation together with the lipid peroxidation may be the possible cause of the necrosis. In our OGD model there is a time-dependent ROS formation during the OGD treatment and lipid peroxidation is also induced. The ROS formation could look strange because this treatment was performed in absence of O_2 (95% N_2/5 % CO_2). However, mitochondrial ROS generation during hypoxia and anoxia has been shown by several authors [24,14,40-43] although the mechanism of this ROS generation, under this condition has not been

well resolved. During reperfusion the ROS generation, the loss in ATP content and the lipid peroxidation reduction are maintained below control values, which is in accordance with the necrotic death that is produced during this time, although this death is lower than during the OGD treatment. This could mean that, after an ischemic process, and when the blood flow is restored, there is a group of neurons which have suffered a big damage and that they are unable to recover themselves, dying by necrosis.

If this reperfusion is performed in presence of 1 μM genistein, a total reversion of necrotic cell death, ROS formation and lipid peroxidation were found as well as a protection for increase in intracellular ATP content, indicating that genistein protects against death through reduction of both ROS and lipid peroxidation formation. This protection against lipid peroxidation may be the cause of a cellular membrane protection. Similar neuroprotection against ischemia mediated by flavonoids has been found by Zhang *et al.* [44] in gerbil's brain subjected to ischemia/reperfusion and by Liang *et al.* [24] in brain hippocampus after global cerebral ischemia.

In the OGD model used here, apoptotic and autophagic cell deaths were also found. Apoptotic death is probably due to the deprivation of trophic factors during the OGD, at least in the shortest treatments (1-5 h), because during these times the higher caspase-3 activity is found when cells are serum deprived and the increment due to the OGD treatment is too low, although it is statistically significant. However, at 24 h of OGD, additional mechanisms seem to be involved since caspase-3 activity induced by the OGD treatment is about a 33% higher than the caspase-3 activity found in cells only deprived of serum. During the reperfusion period, after 2 h of OGD, the apoptosis is practically abolished with respect to the cells treated with OGD. This is, perhaps, due to the presence of trophic factors during this time. Under this condition genistein had no additional neuroprotective effect, result which could be due to the fact that apoptosis is inhibited, under the reperfusion condition. The mechanism of this apoptotic death induced by OGD, and mediated by caspase-3 activation could be due to the intrinsic mitochondrial apoptotic pathway because we found a depolarization of the mitochondrial membrane induced by OGD, which may show a mitochondrial membrane alteration and, as a consequence, an influence in the caspase-3 activation. Mitochondrial membrane depolarization with caspase-3 activation and cytochrome c release was found by Figueroa *et al.* [25] in cortical neurons treated with SNAP, a NO donor. However, an apoptotic cell death mediated by extrinsic pathway could not be discarded. Another point to comment is the fact that during the 24 h of reperfusion, after 1 h of OGD treatment the mitochondrial membrane continue modified, although

in this case an hyperpolarization instead of a depolarization was observed. This mitochondrial membrane alteration could also be the responsible for the necrotic death during the reperfusion time in absence of genistein. The fact that when reperfusion is performed in presence of genistein there was a total reversion of necrosis could signify that this phytoestrogen could mediate mitochondrial membrane reparation. This asseveration is supported by its ability to revert the mitochondrial membrane potential to the control values.

The cortical neurons subjected to OGD also present a process of autophagy because lipidation of protein LC3B is increased. The autophagy was more evident in the first hour of OGD treatment, after, the autophagy decreased but with values higher than in control cells. Under these conditions, this autophagic process could represent a survival mechanism induced to keep the ATP levels as it is shown by several authors [45-47]. However, in our case, during OGD process there is a great ATP depletion which could indicate that in this case autophagy could not be a protective signal. On the other hand, during reperfusion in which cells have the enough nutrients and oxygen, the autophagy is decreased with respect to the OGD treatment but the values are higher than in control cells after 1 and 3 h of OGD. On the other hand, the ATP levels continuously decay and in this case, autophagy only could mean a mechanism of cell death. So it would be possible than during the reperfusion condition many cells die not only by necrosis and apoptosis but also by autophagia. However, when reperfusion is performed in presence of 1 μM genistein, after 1 h of OGD treatment, a total reversion of autophagy was found, indicating that genistein also protects against this death type, although the molecular mechanism of this neuroprotective effect needs to be studied. The interaction among autophagy, apoptosis and necrosis in the hypoxia-ischemia is complex and still a matter of debate and further work is necessary to understand the relationships between these three death mechanisms in brain ischemia.

In conclusion, from all these results we may infer that the OGD treatment (O_2, trophic factors, nutrients and glucose deprivation) produces the following effects: 1) Necrotic cell death which could be induced by the ROS formation, lipid peroxidation increase and the ATP depletion. 2) Apoptotic cell death mediated by caspase-3 activation probably through an intrinsic pathway. 3) Autophagic cell death.

Genistein, applied during the reperfusion period, protects the cells against necrosis and autophagy, by means of a mechanism which could be mediated by their antioxidant action and by a protector effect on cellular and mitochondrial membrane. Thus, our protective post-stress data on neuroprotection, could serve as basis to plan a

clinical trial with genistein in stroke patients.

REFERENCES

[1] M. P. Mattson and R. J. Mark. "Excitotoxicity and Excitoprotection in Vitro," *Advances in Neurology*, Vol.71, 1996, pp 1-30.

[2] U. Dirnagl, C. Iadecola, and M. A. Moskowitz, "Pathobiology of Ischemic Stroke: An Integrated View," *Trends Neuroscience*, Vol. 22, No. 9, 1999, pp 391-397. doi:10.1016/S0166-2236(99)01401-0

[3] L. A. Labiche and J. C. Grotta, "Clinical Trials for Cytoprotection in Stroke," *NeuroRx*, Vol. 1, No. 1, 2004, pp. 46-70. doi:10.1602/neurorx.1.1.46

[4] M. A. de Leciñana and J. A. Egido, "Estrogens as Neuroprotectants against Ischemic Stroke," *Cerebrovascular Diseases*, Vol. 21 No. 2, 2006, pp. 48-53. doi:10.1159/000091703

[5] S. Suzuki, C. M. Brown and P. M. Wise, "Neuroprotective Effects of Estrogens Following Ischemic Stroke," *Frontiers in Neuroendocrinology*, Vol. 30, No. 2, 2009, pp. 201-211. doi:10.1016/j.yfrne.2009.04.007

[6] C. L. Gibson, L. J. Gray, S. P. Murphy and P. M. Bath, "Estrogens and Experimental Ischemic Stroke: A Systematic Review," *Journal of Cerebral Blood Flow & Metabolism*, Vol. 26, No. 9, 2006, pp. 1103-1113.

[7] T. Jover, H. Tanaka, A. Calderone, K. Oguro, M. V. Bennett, A. M. Etgen and R. S. Zukin, "Estrogen Protects against Global Ischemia-Induced Neuronal Death and Prevents Activation of Apoptotic Signaling Cascades in the Hippocampal Ca1," *Journal of Neuroscience*, Vol. 22, No. 6, 2002, pp. 2115-2124.

[8] C. A. Singer, X. A. Figueroa-Masot, R. H. Batchelor and D. M. Dorsa. "The Mitogen-Activated Protein Kinase Pathway Mediates Estrogen Neuroprotection after Glutamate Toxicity in Primary Cortical Neurons," *Journal of Neuroscience*, Vol. 19, No. 7, 1999, pp. 2455-2463.

[9] K. Honda, H. Sawada, T. Kihara, M. Urushitani, T. Nakamizo, A. Akaike and S. Shimohama, "Phosphatidylinositol 3-Kinase Mediates Neuroprotection by Estrogen in Cultured Cortical Neurons," *Journal of Neuroscience Research*, Vol. 60, No. 3, 2000, pp. 321-327. doi:10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.0.CO;2-T

[10] E. A. Sribnick, S. K. Ray, M. W. Nowak, L. Li and N. L. Banik, "17 Beta-Estradiol Attenuates Glutamate-Induced Apoptosis and Preserves Electrophysiologic Function in Primary Cortical Neurons," *Journal of Neuroscience Research*, Vol. 76, No. 5, 2004, pp. 688-696. doi:10.1002/jnr.20124

[11] J. Nilsen, and R. D. Brinton, "Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate," *Endocrinology*, Vol. 13, No. 6, 2002, pp. 205-212. doi:10.1210/en.143.1.205

[12] H. Cimarosti, I. R.Siqueira, L. L. Zamin, M. Nassif, R. Balk, R. Frozza, C. Dalmaz, C. A. Netto and C. Salbego, "Neuroprotection and Protein Damage Prevention by Estradiol Replacement in Rat Hippocampal Slices Exposed to Oxygen-Glucose Deprivation," *Neurochemical Research*, Vol. 30, 2005, pp. 583-589. doi:10.1007/s11064-005-2693-1

[13] S. Chen, J. Nilsen and R. D. Brinton, "Dose and Temporal Pattern of Estrogen Exposure Determines Neuroprotective Outcome in Hippocampal Neurons: Therapeutic Implications," *Endocrinology*, Vol. 147, No. 11, 2006, pp. 5303-5313. doi:10.1210/en.2006-0495

[14] E. Candelario-Jalil, N. H. Mhadu, S. M. Al-Dalain, G. Martinez and O. S. León, "Time Course of Oxidative Damage in Differenr Brain Regions Following Transient Cerebral Ischemia in Gerbis," *Neurochemical Research*, Vol. 41, No. 3, 2001, pp. 233-241.

[15] D. Amantea, R. Russo, G. Bagetta and M. T.Corasaniti. "From Clinical Evidence to Molecular Mechanisms Underlying Neuroprotection Afforded by Estrogens," *Pharmacol Research*, Vol. 52, No. 2, 2005, pp. 119-132. doi:10.1016/j.phrs.2005.03.002

[16] V. N. Trieu and F. M. Uckun, "Genistein is Neuroprotective in Murine Models of Familial Amyotrophic Lateral Sclerosis and Stroke," *Biochemical and Biophysical Research Communications*, Vol. 258, No. 3, 1999, pp 685-688. doi:10.1006/bbrc.1999.0577

[17] D. A. Schreihofer and L. Redmond. "Soy Phytoestrogens are Neuroprotective against Stroke-Like Injury in Vitro," *Neuroscience*, Vol. 158, No. 2, 2009, pp 602-609. doi:10.1016/j.neuroscience.2008.10.003

[18] M. C. Burguete, G. Torregrosa, F. J. Perez-Asensio, M. Castello-Ruiz, J. B. Salom, J. V. Gil and E. Alborch, "Dietary Phytoestrogens Improve Stroke Outcome after Transient Focal Cerebral Ischemia in Rats," *European Journal of Neuroscience*, Vol. 23, No. 2, 2006, pp. 703-710. doi:10.1111/j.1460-9568.2006.04599.x

[19] L. Zhao, Q. Chen and R. D. Brinton, "Neuroprotective and Neurotrophic Efficacy of Phytoestrogens in Cultured Hippocampal Neurons," *Experimental Biology and Medicine*, Vol. 227, No. 7, 2002, pp. 509-519.

[20] N. J. Linford and D. M Dorsa, "17 Beta-Estradiol and the Phytoestrogen Genistein Attenuate Neuronal Apoptosis Induced by the Endoplasmic Reticulum Calcium-Atpase Inhibitor Thapsigargin," *Steroids*, Vol. 67, No. 13-14, 2002, pp. 1029-1040. doi:10.1016/S0039-128X(02)00062-4

[21] H. Zeng, Q. Chen and B. Zhao, "Genistein Ameliorates Beta-Amyloid Peptide (25-35)-Induced Hippocampal Neuronal Apoptosis," *Free Radical Biology and Medicine*, Vol. 36, No. 2, 2004, pp. 180-188. doi:10.1016/j.freeradbiomed.2003.10.018

[22] H. Inoue, H. Ohtaki, T. Nakamachi, S. Shioda and Y. Okada, "Anion Channel Blockers Attenuated Delayed

Neuronal Cell Death Induced by Transient Forebrain Ischemia," *Journal of Neuroscience Research*, Vol. 85, No. 7, 2007, pp. 1427-1435. doi:10.1002/jnr.21279

[23] K. P. Ho, L. Li, L. Zhao and Z. M. Qjan, "Genistein Protects Primary Cortical Neurons from Iron Induced Lipid Peroxidation," *Molecular and Cellular Biochemistry*, Vol. 247, No. 1-2, 2003, pp. 219-222. doi:10.1023/A:1024142004575

[24] H. W. Liang, S. F. Qju, J. Shen, L. N. Sun, J. Y. Wang, I. C. Bruce and Q. Xia, "Genistein Attenuates Oxidative Stress and Neuronal Damage Following Transient Global Cerebral Ischemia in Rat Hippocampus," *Neuroscience Letters*, Vol. 438. No. 1, 2008, pp. 116-120. doi:10.1016/j.neulet.2008.04.058

[25] S. Figueroa, M. J. Oset-Gasque, C. Arce, C. Martínez-Honduvilla and M. P. González, "Mitochondrial Involvement in Nitric Oxide-Induced Cellular Death in Cortical Neurons in Culture," *Journal of Neuroscience Research*, Vol. 83, No. 3, 2006, pp. 441-449. doi:10.1002/jnr.20739

[26] M. Bradford, "A Rapid Sensitive Method for the Quantization of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," *Analytical Biochemistry*, Vol. 72, 1976, pp. 248-254. doi:10.1016/0003-2697(76)90527-3

[27] L. Tenneti, D. M. D'Emilia, C. M. Troy and S.A Lipton, "Role of Caspases in N-Methyl-D-Aspartate-Induced Apoptosis in Cerebrocortical Neurons," *Journal of Neurochemistry*, Vol. 71, No. 3, 1998, pp. 946-959. doi:10.1046/j.1471-4159.1998.71030946.x

[28] A. S. Waggoner. "The Use of Cyanine Dyes for the Determination of Membrane Potentials in Cells, Organelles, and Vesicles," *Methods in Enzymology*, Vol. 55, 1979, pp 689-695. doi:10.1016/0076-6879(79)55077-0

[29] C. G. Fraga, P. I. Oteiza, M. S. Golup, M. E. Gershwin and C. L. Keen, "Effects of Aluminium on Brain Lipid Peroxidation," *Toxicology Letters*, Vol. 51, No. 2, 1990, pp. 213-219. doi:10.1016/0378-4274(90)90212-5

[30] L. Xue, G. C. Fletcher and A. M. Tolkovsky, "Autophagy is Activated by Apoptotic Signaling in Sympathetic Neurons: An Alternative Mechanism of Death Execution," *Molecular and Cellular Neuroscience*, Vol. 14, No. 3, 1999, pp. 180-198. doi:10.1006/mcne.1999.0780

[31] P. Codogno and A. J. Mejier, "Autophagy and Signalling: Their Role in Cell Survival and Cell Death," Cell Death and Differentiation, Vol. 12 No. S2, 2005, pp. 1509-1518. doi:10.1038/sj.cdd.4401751

[32] F. Adhami, G. Liao, Y. M. Morozov, A. Schloemer, V. J. Schmithorst, J. N. Lorenz, R. S. Dunn, C. V. Vorhees, M. Wills-Karp, J. L. Degen, R. J. Davis, N. Mizushima, P. Rakic, B. J. Dardzinski, S. K. Holland, F. R. Sharp and C. Y. Kuan, "Cerebral Ischemia-Hypoxia Induces Intravascular Coagulation and Autophagy," *American Journal of Pathology*, Vol. 169, No. 2, 2006, pp. 566-583. doi:10.2353/ajpath.2006.051066

[33] W. Balduini, S. Carloni and G. Buonocore, "Autophagy in Hypoxia-Ischemia Induced Brain Injury: Evidence and Speculations," Autophagy, Vol. 5, No. 2, 2009, pp. 221-223. doi:10.4161/auto.5.2.7363

[34] S. Barnes, "Evolution of the Health Benefits of Soy Isoflavones," *Proceedings of the Society for Experimental Biology and Medicine*, Vol. 217, No. 3, 1998, pp. 386-392.

[35] D. Altavilla, A. Crisafulli, H. Marini, M. Esposito, R. D. Anna, F. Corrado, A. Bitto and F. Squadrito, "Cardiovascular Effects of the Phytoestrogen Genistein," *Cardiovascular and Hematological Agents in Medicinal Chemistry*, Vol 2, No. 2, 2004, pp. 179-186. doi:10.2174/1568016043477297

[36] H. J. Wu and W. H. Chan, "Genistein Protects Methylglioxal-Induced Oxidative DNA Damage and Cell Injury in Human Mononuclear Cells," Toxicology in Vitro, Vol. 21, No. 3, 2007, pp. 335-342. doi:10.1016/j.tiv.2006.09.002

[37] M. S. Kindy, "Inhibition of Tyrosine Phosphorylation Prevents Delayed Neuronal Death Following Cerebral Ischemia," *Journal of Cerebral Blood Flow & Metabolism*, Vol. 13, No.3, 1993, pp. 372-377.

[38] R. Traystman, J. R. Kirsch and C. Koehler, "Oxygen Radicals Mechanism of Brain Injuria Following Ischemia and Reperfusion," *Journal of Applied Physiology*, Vol. 71, No. 4, 1991, pp. 1185-1195.

[39] Y. Matsuo, T. Kihara, M. Ikeda, M. Ninomiya, H. Onodera and K. Kogure, "Role of Platelet-Activating Factor and Thromboxane A2 in Radical Production during Ischemia and Reperfusion of the Rat Brain," *Brain Research*, Vol. 709, No. 2, 1996, pp. 296-302. doi:10.1016/0006-8993(95)01324-5

[40] T. Kimova and N. S. Chandel, "Mitochondrial Complex Iii Regulates Hypoxic Activation of HIF," *Cell Death and Differentiation*, Vol. 15, No. 4, 2008, pp. 660-666. doi:10.1038/sj.cdd.4402307

[41] P. H. Chan, "Role of Oxidants in Ischemic Brain Damage," *Stroke*, Vol. 27, No. 6, 1996, pp. 1124-1129.

[42] H. Friberg, T. Wieloch and R. F. Castilho, "Mitochondrial Oxidative Stress after Global Brain Ischemia in Rats," *Neuroscience Letters*, Vol. 334, No. 2, 2002, pp. 111-114. doi:10.1016/S0304-3940(02)01116-3

[43] M. A. Moro, A. Almeida, J. P. Bolaños and I. Lizasoain, "Mitochondrial Respiratory Chain and Free Radical Generation in Stroke," *Free Radical Biology & Medicine*, Vol. 39, No. 10, 2005, pp. 1291-1304. doi:10.1016/j.freeradbiomed.2005.07.010

[44] D. L. Zhang, Y. T. Zhang, J. J. Yin and B. L. Zhao, "Oral Administration of Crataegus Flavonoids Protects against Ischemia/Reperfusion Brain Damage in Gerbils," *Journal of Neurochemistry*, Vol. 90, No. 1, 2004, pp. 211-219. doi:10.1111/j.1471-4159.2004.02480.x

[45] V. E. Dosenko, V. S. Nagibin, L. V. Tumanovska and A. A. Moibenko, "Protective Effect of Autophagy in Anoxia-Reoxigenation of Isolated Cardiomyocyte?" *Autophagy*, Vol. 2, No. 4, 2006, pp. 305-306.

[46] M. Komatsu, S. Waguri, T. Chiba, S. Murata, J. Iwata, I. Tanida, T. Ueno, M. Koike, Y. Uchiyama, E. Komonani and K. Tanaka, "Loss of Autophagy in the Central Nervous System Causes Neurodegeneration in Mice," *Nature*, Vol. 441, No. 7095, 2006, pp. 880-884. doi:10.1038/nature04723

[47] T. Hara, K. Nakamura, M. Matsui, A. Yamamoto, Y. Nakahara, R. Suzuki-Migishima, M. Yokoyama, K. Mishima, I. Saito, H. Okano and N. Mizushima, "Supression of Basal Autophagy in Neuronal Cells Causes Neurodegenerative Disease in Mice," *Nature*, Vol. 441, No. 7095, 2006, pp. 885-889. doi:10.1038/nature04724